Mouse SPARC-like 1/SPARCL1 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB2836
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Ile17-Phe650
Accession # P70663
Specificity
Clonality
Host
Isotype
Applications for Mouse SPARC-like 1/SPARCL1 Antibody
Western Blot
Sample: Recombinant Mouse SPARC-like 1/SPARCL1 (Catalog # 4547-SL)
Reviewed Applications
Read 1 review rated 5 using MAB2836 in the following applications:
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: SPARC-like 1/SPARCL1
SPARCL1 (Secreted Protein, Acidic and Rich in Cysteines-like 1), also known as hevin, SC1 or MAST9, is a member of the SPARC family of extracellular glycoproteins (1, 2). SPARCL1 is an anti-adhesive protein that is widely expressed in tissues such as brain, heart, lung, muscle and kidney, but not liver (3, 4). Mouse SPARCL1 contains a 16 amino acid (aa) signal sequence and a 634 aa mature region that contains four domains: a 403 aa N-terminal acidic region, a 23 aa follistatin‑like domain, a 55 aa kazal-like segment and a 148 aa calcium‑binding domain that contains two EF hand motifs (3, 4). Mouse mature SPARCL1 shares 89%, 67%, 63%, 61%, 60%, and 58% aa identity with rat, human, equine, canine, porcine, and bovine SPARCL1, respectively. The follistatin-like, kazal-like and calcium‑binding domains of SPARCL1 show 61% aa identity with corresponding regions of SPARC. SPARCL1 is predicted at 75 kDa, but migrates at ~130 kDa, which has been explained either by disulfide-linked homodimerization or by glycosylation and high acidity (3‑5). Some truncated forms have been reported. In mouse, a 55 kDa C‑terminal fragment is the only form in kidney and represent a portion of SPARCL1 in other tissues (6). In humans, a 25 kDa form is increased in liver tumors that are encapsulated, while the full-length form is downregulated in many epithelial cell-derived tumors (7, 8). SPARCL1 inhibits adhesion and spreading on a variety of substrates (5, 9). It is thought to cause antiadhesive signaling that terminates neuronal migration, consistent with production by glial and neuronal cells during development or in response to trauma (10). In tonsillar high endothelial venules (HEV), SPARCL1 may induce endothelial cell dissociation, promoting extravasation (3). SPARCL1 binds collagen; in mice, deletion causes dermal collagen fibrils that are smaller in diameter and deficient in decorin (6, 11).
References
- Framson, P.E. and E.H. Sage (2004) J. Cell. Biochem. 92:679.
- Sullivan, M.M. and E.H. Sage (2004) Int. J. Biochem. Cell Biol. 36:991.
- Girard, J.P. and T.A. Springer (1995) Immunity 2:113.
- Bendik, I. et al. (1998) Cancer Res. 58:626.
- Brekken, R.A. et al. (2004) J. Histochem. Cytochem. 52:735.
- Hambrock, H.O. et al. (2003) J. Biol. Chem. 278:11351.
- Lau, C.P. et al. (2006) J. Pathol. 210:469.
- Isler, S.G. et al. (2001) Int. J. Oncol. 18:521.
- Girard, J.P. and T.A. Springer (1996) J. Biol. Chem. 271:4511.
- Gongidi, V. et al. (2004) Neuron 41:57.
- Sullivan, M.M. et al. (2006) J. Biol. Chem. 281:27621.
Alternate Names
Gene Symbol
UniProt
Additional SPARC-like 1/SPARCL1 Products
Product Documents for Mouse SPARC-like 1/SPARCL1 Antibody
Product Specific Notices for Mouse SPARC-like 1/SPARCL1 Antibody
For research use only